BPG is committed to discovery and dissemination of knowledge
Editorial
Copyright ©The Author(s) 2025.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 106116
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.106116
Table 1 Healthcare payment and survival outcome of esophageal cancer
Payment situation
Prognosis
Potential major explanations
Basic medical insurance
    UEBMI vs URRBMIUnfavorableLess TNM stage I-II diseases, and more TNM stage IV diseases in UEBMI subset. More patients with TNM stage IV esophageal cancers were willing to undertake active therapies if supported by UEBMI
OOP rate
    > 60% vs ≤ 60%FavorableMore TNM stage I-II diseases, and less TNM stage IV diseases in high OOP subset. Potentially higher education level, better awareness of cancer prevention and control, more accessible healthcare resources, and better affordable finance
Per 10% incremental WTP
    UEBMI subsetFavorableIncreasing the accessibility of active therapies in UEBMI subset which had more patients with advanced diseases
    OOP rate > 60% subsetUnfavorableAs a post-hoc situation, associated with advanced stages migrating correspondingly